Menu
Search
|

Menu

Close
X

Innovate Biopharmaceuticals Inc INNT.OQ (NASDAQ Stock Exchange Capital Market)

6.18 USD
-0.38 (-5.79%)
As of Jul 20
chart
Previous Close 6.56
Open 6.59
Volume 84,528
3m Avg Volume 93,221
Today’s High 6.59
Today’s Low 6.06
52 Week High 50.50
52 Week Low 3.43
Shares Outstanding (mil) 25.70
Market Capitalization (mil) 168.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
4
FY15
8
EPS (USD)
FY18
-0.760
FY17
-9.308
FY16
-8.111
FY15
-10.839
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
181.06
8.11
Price to Book (MRQ)
vs sector
20.24
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
43.43
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-494.49
13.18
Return on Equity (TTM)
vs sector
-514.78
15.09

EXECUTIVE LEADERSHIP

Sandeep Laumas
Executive Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jay Madan
President, Director, Since 2018
Salary: --
Bonus: --
Christopher Prior
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Saira Ramasastry
Director, Since 2018
Salary: --
Bonus: --
Lorin Johnson
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8480 Honeycutt Rd Ste 120
RALEIGH   NC   27615-2261

Phone: +1919.2751933
Site:

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.

SPONSORED STORIES